JAK2V617F and mCALR are the two primary driver mutations responsible for disease progression and poor prognosis in the majority of MPN patients ... wave of disease-modifying therapies for MPN patients.
About MPN Research Foundation MPN Research Foundation is dedicated to funding and advancing original research in pursuit of new treatments — and eventually a cure — for essential thrombocythemia (ET), ...